Medicilon/MPI Preclinical Research-Shanghai Receives AAALAC Certification
Medicilon/MPI Preclinical Research-Shanghai has been recognized as an accredited International Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility. This accreditation further underscores the companyâ€™s commitment to quality research. The AAALAC initiative was led by Lijie Fu, PhD, Executive Vice President of Operations, a national returnee with substantial industry, scientific and CRO experience.
Medicilon/MPI Preclinical Research-Shanghai has been recognized as an accredited International Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility. This accreditation further underscores the company’s commitment to quality research. The AAALAC
initiative was led by Lijie Fu, PhD, Executive Vice President of Operations, a national returnee with substantial industry, scientific and CRO experience. “We recognized that full AAALAC certification is essential for establishing credibility within the industry.We understand and appreciate the need for these standards, and have been diligently working to achieve this goal.With our dedicated leadership and
this accreditation, we are now able to enhance our capabilities to further meet the needs of our Sponsors,” says Bill Parfet, MBA, Chairman of the Board of Medicilon/MPI Preclinical Research–Shanghai, and Chairman and CEO of MPI Research.
Full AAALAC accreditation is a reflection of high standards, accountability and a commitment to animal welfare. It is recognized as a milestone and benchmark for responsible and ethical laboratory animal care, and also sets standards for veterinary medical care, occupational health and safety, and physical plant or HVAC standards that equal or exceed many non-accredited Western institutions. The company attributes the achievement of this certification to the dual efforts of the dedicated scientific management team, led by Mingli Chen, MD, MS, DABT, VP of Research, along with a multidisciplinary team provided by one of the parent company’s, MPI Research. The team members from MPI Research accepted long-term assignments in Shanghai to train the local staff in Good Laboratory Practices (GLP) and AAALAC standards. “We are fortunate to have such a knowledgeable and enthusiastic team bringing our newly formed company up to the regulatory standards of the industry.We pride ourselves in the excellence of work that we produce and appreciate the steps that it takes to reach this level of quality,” says Jintao Zhang, PhD, CEO of Medicilon/MPI Preclinical Research- Shanghai. Dr. Zhang co-founded Medicilon Shanghai, the second parent company of this joint venture, and served as its CEO in 2008. Medicilon/MPI Preclinical Research-Shanghai provides global pharmaceutical and biotechnology companies with high quality preclinical drug discovery and development studies in an Asian facility that meet worldwide regulatory standards.